Intervention not reported
All‐cause mortality at maximum · adults with compensated or decompensated advanced chronic liver disease
It is very uncertain whether the intervention changes all‐cause mortality at maximum (very low certainty).
1 finding from 1 review
All‐cause mortality maximum · patients with coronary heart disease
Antibiotics showed no clear difference in all‐cause mortality at maximum compared with placebo or no intervention (high certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality at maximum · patients without heart failure
The intervention probably leads to lower all‐cause mortality at maximum (moderate certainty).
1 finding from 1 review
All‐cause mortality maximum · newborns with late‐onset sepsis
It is very uncertain whether cefazolin plus amikacin changes all‐cause mortality maximum compared with vancomycin plus amikacin (very low certainty).
1 finding from 1 review
All‐cause mortality maximum · newborns with late‐onset sepsis
It is very uncertain whether vancomycin plus gentamicin changes all‐cause mortality maximum compared with vancomycin plus aztreonam (very low certainty).
1 finding from 1 review
All‐cause mortality maximum · newborns with late‐onset sepsis
It is very uncertain whether ticarcillin plus clavulanic acid changes all‐cause mortality maximum compared with flucloxacillin and gentamicin (very low certainty).
1 finding from 1 review
All‐cause mortality maximum · newborns with late‐onset sepsis
It is very uncertain whether cloxacillin plus amikacin changes all‐cause mortality maximum compared with cefotaxime plus gentamicin (very low certainty).
1 finding from 1 review
All‐cause mortality maximum · newborns with late‐onset sepsis
It is very uncertain whether meropenem changes all‐cause mortality maximum compared with standard care (very low certainty).
1 finding from 1 review
All‐cause mortality maximum · neonates with early‐onset sepsis
It is very uncertain whether ampicillin plus gentamicin changes all‐cause mortality maximum compared with penicillin plus gentamicin (very low certainty).
1 finding from 1 review
All‐cause mortality maximum · neonates with early‐onset sepsis
It is very uncertain whether piperacillin changes all‐cause mortality maximum compared with ampicillin plus amikacin (very low certainty).
1 finding from 1 review
All‐cause mortality maximum · neonates with early‐onset sepsis
1 finding from 1 review
All‐cause mortality maximum · neonates with early‐onset sepsis
It is very uncertain whether piperacillin plus tazobactam changes all‐cause mortality maximum compared with amikacin (very low certainty).
1 finding from 1 review
All‐cause mortality maximum · neonates with early‐onset sepsis
It is very uncertain whether ticarcillin plus clavulanic acid changes all‐cause mortality maximum compared with piperacillin plus gentamicin (very low certainty).
1 finding from 1 review
All‐cause mortality maximum · neonates and children with hospital‐acquired pneumonia
It is very uncertain whether cefepime changes all‐cause mortality Maximum compared with ceftazidime (very low certainty).
1 finding from 1 review
All‐cause mortality maximum · neonates and children with hospital‐acquired pneumonia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality maximum · patients with suspected or diagnosed myocardial infarction
Beta‐blockers probably leads to lower all‐cause mortality at maximum compared with placebo or no intervention (moderate certainty).
1 finding from 1 review
All‐cause mortality maximum · adults with chronic hepatitis C
It is very uncertain whether direct‐acting antivirals changes all‐cause mortality at maximum compared with control (very low certainty).
1 finding from 1 review
All‐cause mortality maximum · adults with chronic hepatitis C
It is very uncertain whether direct‐acting antivirals withdrawn from the market changes all‐cause mortality at maximum compared with control (very low certainty).
1 finding from 1 review
All‐cause mortality maximum · patients with acute coronary syndrome
Drug‐eluting stents showed no clear difference in all‐cause mortality at maximum compared with bare‐metal stents (low certainty).
1 finding from 1 review
Mortality Number of deaths at maximum · participants with unresectable hepatocellular carcinoma
External beam radiotherapy (EBRT) plus transarterial… may leads to lower all‐cause mortality (at maximum 1‐year compared with TACE alone (low certainty).
1 finding from 1 review